Product Overview
[Drug Name]
Generic Name: Irbesartan Dispersible Tablets
Trade Name: Yiling Irbesartan Dispersible Tablets 75mg*20 Tablets
Pinyin Full Code: YiLing EBeiShaTanFenSanPian 75mg*20Tablets
[Main Ingredients]
The main ingredient of this product is irbesartan. Excipients: Cross-linked polyvinylpyrrolidone, microcellulose, lactose, povidone K30, saccharin sodium, silicon dioxide, magnesium stearate. Chemical Name: 2-Butyl-3-[4-[2-(1H-tetrazol-5-yl)phenyl]benzyl]-1,3-diazaspiro[4.4]wang-1-en-4-one. Molecular Formula: C25H28N6O Molecular Weight: 428.54 (See package insert for details of excipients).
[Properties]
This product is white or off-white tablets.
[Indications/Main Functions]
Treatment of essential hypertension. Treatment of type 2 diabetic nephropathy with hypertension.
[Specifications]
75mg * 20 tablets
[Dosage and Administration]
The recommended initial and maintenance dose is 150mg daily. Dietary considerations have no impact on medication administration. Generally, 150mg of irbesartan once daily provides better 24-hour blood pressure control than 75mg. However, for certain patients, particularly those undergoing hemodialysis and those over 75 years of age, a 75mg initial dose may be considered. For patients whose blood pressure is not effectively controlled with 150mg of irbesartan once daily, the dose can be increased to 300mg, or other antihypertensive medications can be added. In particular, the addition of diuretics such as hydrochlorothiazide has been shown to have an additive effect. For hypertensive patients with type 2 diabetes, the initial treatment dose should be 150mg once daily, increasing to 300mg once daily as a maintenance dose for nephropathy. Clinical studies have demonstrated that irbesartan benefits the kidneys of hypertensive patients with type 2 diabetes. In the study, irbesartan was used in combination with other antihypertensive medications, if necessary, to lower patients' blood pressure to target values. (See package insert for other details.)
[Adverse Reactions]
See package insert for details.
[Contraindications]
See package insert for details.
[Precautions]
See package insert for details.
